A Single-Center, Randomized, Open-Label, Controlled Trial of Orlistat Combined With Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Endometrial Hyperplasia With Low Progesterone Receptor Expression

This is a single-center, randomized, open-label, controlled clinical trial evaluating whether adding orlistat to standard progestin therapy can improve treatment response in patients receiving fertility-sparing treatment for early-stage endometrial cancer (grade 1-2) or atypical endometrial hyperplasia.
Progestin is the standard drug used to preserve the uterus and fertility in these patients, but about 30% of patients respond poorly because the progesterone receptor (PR) in the endometrium is lost or reduced. Laboratory studies by the research team have shown that orlistat, a widely used oral weight-loss drug that blocks fat absorption, can raise PR levels and restore sensitivity to progestin.
The study will enroll 48 patients (age 45 years or younger, body mass index 24 kg/m2 or higher) who still have residual disease and low PR expression after at least 3 months of first-line progestin therapy. Participants will be randomly assigned in a 1:1 ratio to receive either progestin plus orlistat (experimental group) or progestin alone (control group) for 3 months, followed by 24 months of follow-up. The main goal is to compare the change in PR expression from baseline after 3 months of treatment. The study will also assess how many patients achieve complete disease reversal, time to complete response, recurrence, pregnancy and live-birth rates, safety, and changes in body weight and metabolic measures.

Start Date01 Jul 2026

Sponsor / Collaborator

Peking University People's Hospital

PACTR202606518409008

/ SuspendedPhase 4IIT

The Effect of Metformin versus Orlistat on Cardiovascular and Metabolic profile in Obese Children: A Randomized Control Trial

Start Date01 May 2026

Sponsor / Collaborator

Tanta University

NCT07301437

/ Not yet recruitingPhase 4IIT

A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.

To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.

Start Date01 May 2026

Sponsor / Collaborator-

100 Clinical Results associated with Orlistat

100 Translational Medicine associated with Orlistat

100 Patents (Medical) associated with Orlistat

2,599

Literatures (Medical) associated with Orlistat

31 Dec 2026·Artificial Cells Nanomedicine and Biotechnology

Green synthesis of ZnO nanoparticles using pomegranate husk extract: comparative evaluation of antioxidant, enzyme inhibition, and cytotoxic properties

Article

Author: Li, Fang ; Djearamane, Sinouvassane ; Lim, Sharon Chia-Yen ; Wong, Ling-Shing ; Lim, Boon-Hoe ; Cheah, Shi-Yan ; Koh, Ming-Xiu ; Tey, Lai-Hock ; Aminuzzaman, Mohammod ; Subramaniam, Hemaroopini ; Phang, You-Kang

The prevalence of obesity has risen sharply in recent years, prompting the need for safer and more biocompatible therapeutic alternatives to conventional anti-obesity drugs. In this study, zinc oxide nanoparticles (ZnO NPs) were synthesized using pomegranate husk extract via two green approaches: conventional heating and microwave-assisted synthesis. Structural and morphological characterizations confirmed successful nanoparticle formation. Microwave-assisted ZnO nanoparticles (MA-ZnO NPs) exhibited smaller particle dimensions and narrower polydispersity compared with conventionally synthesized ZnO NPs. Both types of ZnO NPs demonstrated notable antioxidant activity (>62% scavenging in DPPH and ABTS assays) and strong inhibitory effects against pancreatic lipase and α-amylase (>70%), comparable to standard drugs such as orlistat and acarbose. Cytotoxicity assays using Vero cells confirmed high biocompatibility, with >60% cell viability. This work presents a comparative evaluation of two green synthesis methods and highlights the potential of biogenic ZnO NPs as multifunctional agents for oxidative stress reduction and enzyme inhibition in obesity management.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Pharmacological inhibition of IRAK1/4 ameliorates high-fat diet-induced vascular dysfunction and cognitive impairment

Article

Author: Barthwal, Manoj Kumar ; Yadav, Prem N ; Agarwal, Heena ; Kumar, Dinesh ; Kumar, Sakesh ; Kaur, Gagandeep

PURPOSE:

Interleukin 1 receptor-associated kinase 1, 4 (IRAK 1/4) inhibitor exerts anti-inflammatory and immuno-modulatory effects; however, its role in high-fat diet-induced vascular dysfunction and cognitive impairment is not known, and therefore investigated in the present study.

METHOD & RESULTS:

Animals were fed either a high-fat diet (60% Kcal fat) or a chow diet (10% Kcal fat) for 12 weeks to induce hyperlipidemia and weight gain. High-fat diet-fed animals were then treated with vehicle, IRAK1/4 inhibitor (2.2 mg/kg, i.p.) and a reference drug, Orlistat (20 mg/kg, oral gavage), for 4 additional weeks. Protein levels were assessed by ELISA or Western blotting, and mRNA by RT-PCR. IRAK1/4 inhibitor and reference drug, Orlistat treatment, prevented HFD-induced increase in body weight gain, fasting blood glucose and plasma lipids, improved discrimination between the familiar and the novel arm in the Y-Maze test, alleviated percent avoidance in two-way active avoidance, and freezing percent in contextual fear conditioning test. The treatments attenuated the levels of systemic inflammatory cytokines IL-1β, CRP, as well as TNF-α, IL-6 and protein expression of Iba-1, GFAP, HIF-1α, and restored the BDNF levels in the pre-frontal cortex of HFD-fed treated mice. IRAK 1/4 inhibitor exerted these effects by blocking proteasomal degradation of IκB-α protein in the pre-frontal cortex of HFD-treated mice. In addition, the treatments prevented HFD-induced increase in vascular ICAM-1, VCAM-1, MCP-1, COX-1 and COX-2 mRNA expression, and restored vascular eNOS mRNA levels as well as the Acetylcholine (300 ρM-300 μM) induced relaxations of PE (1 µM) pre-contracted aortic rings.

CONCLUSION:

IRAK1/4 inhibitor attenuates HFD-induced inflammation, vascular dysfunction and cognitive impairment in obese mice.

01 Dec 2026·AMERICAN JOURNAL OF CARDIOLOGY

GLP-1 Analogues and Long-Term Outcomes in Adults With Obesity and Elevated CRP: A Real-World Matched Cohort Study

Article

Author: Keen, Susan K ; Sheashaa, Hesham ; Shah, Stuti ; Abusafia, Mohammed ; Ospina, Susan ; Jadam, Shada ; Desai, Milind Y ; Cho, Leslie ; Kaelber, David

Obesity is frequently accompanied by low-grade systemic inflammation and increased cardiovascular risk. We evaluated whether glucagon-like peptide-1 receptor agonist (GLP-1 RA) exposure was associated with improved long-term outcomes among adults with obesity and C-reactive protein (CRP) levels of 3 to 10 mg/L. Using the TriNetX Global Collaborative Network, adults with body mass index ≥30 kg/m² who received a GLP-1 RA were compared with an active-comparator cohort receiving metformin, orlistat, or phentermine without GLP-1 RA exposure. Following 1:1 propensity-score matching, 50,009 patients were included in each cohort and followed for up to 3,650 days. GLP-1 RA exposure was associated with a lower hazard of the primary composite outcome of all-cause mortality, acute myocardial infarction, and ischemic stroke (hazard ratio [HR] 0.799, 95% confidence interval [CI] 0.772-0.825; p < 0.001), driven primarily by lower all-cause mortality (HR 0.608, 95% CI 0.578-0.640; p < 0.001). Ischemic stroke, arrhythmias, and heart failure with reduced ejection fraction were modestly lower, whereas acute myocardial infarction and incident heart failure with preserved ejection fraction did not differ significantly between cohorts. In conclusion, GLP-1 RA exposure was associated with lower long-term composite clinical events among adults with obesity and CRP levels of 3 to 10 mg/L, predominantly reflecting lower mortality; prospective studies incorporating longitudinal weight and CRP measurements are needed to evaluate potential mediating mechanisms.

News (Medical) associated with Orlistat

22 Aug 2025

·pharma.economictimes.indiatimes.com

GLP-1 drugs linked to lower cancer risks

London: GLP-1 drugs for diabetes and weight loss may influence patients' cancer risk , usually lowering it but sometimes possibly increasing it, new findings suggest. U.S. researchers reviewed 10 years of medical records from 43,317 users and 43,315 similar nonusers of Novo Nordisk 's type 2 diabetes drugs Victoza and Ozempic or its weight-loss medication Wegovy , or Eli Lilly's Mounjaro for diabetes or Zepbound for weight loss. All volunteers were at risk for obesity-related cancers. Each year, out of every thousand participants, 13.6 users of GLP-1 drugs were diagnosed with any of 14 types of cancer, compared to 16.6 nonusers, the researchers reported in JAMA Oncology. After accounting for individual risk factors, the overall cancer risk was 17 per cent lower in GLP-1 users. In particular, GLP-1 use was associated with a 25 per cent lower risk of endometrial cancer , a 47 per cent lower risk of ovarian cancer and a 31 per cent lower risk of meningioma. GLP-1 drugs were also associated with a slight increase in risk for kidney cancer. The increase was not statistically significant, meaning it could have been due to chance - but an earlier study also found a higher risk of kidney cancer with use of GLP-1 drugs for diabetes, the authors note. Observational studies like this one cannot prove cause and effect, and it's impossible to know whether any reductions in cancer risk were due to the GLP-1 drugs themselves or to drug-induced weight loss. Still, the researchers said, "Given that more than 137 million individuals in the U.S. are currently eligible for GLP-1 therapies, even modest changes in cancer risk could have substantial public health implications." CONDENSING HOURS-LONG IV INFUSIONS INTO QUICK INJECTIONS New technology may allow quick injections of drugs that currently require slow intravenous infusions, researchers say. The high volume of fluid required to administer so-called antibody drugs - often used for cancer, autoimmune diseases and metabolic disorders - means patients must submit to time-consuming intravenous drips. That's because the antibodies, which are proteins, only remain stable in fluids at low concentrations. A new method of coating the proteins, however, allows them to be stored in the high concentrations necessary for administration with a standard syringe or autoinjector device, researchers reported in Science Translational Medicine. To pack the proteins into liquid at high concentrations but keep them stable and functional, the researchers encased tiny particles in a substance they developed called MoNi. The coating prevents particles from dissolving or sticking together in fluid and keeps them dry and stable, the researchers said. "We ended up with something that looks like a candy-coated chocolate, where the protein is on the inside and our special polymer forms a solid, glassy coating on the outside," study leader Eric Appel of Stanford University said in a statement. In tests using three different proteins - albumin, human immunoglobulin and a monoclonal antibody treatment for COVID - the researchers were able to inject a solution with more than double the concentration of typical liquid injections. The new method "potentially works with any biologic drug, so that we can inject it easily," Appel said. "That takes these treatments from a several-hour ordeal at a clinic with an IV infusion to something you can do in seconds with an autoinjector at your house," Appel said. BOBA TEA-LIKE BEADS BEING DEVELOPED FOR WEIGHT LOSS Plant-based microbeads resembling boba tea pearls helped rats lose weight on a high-fat diet and may one day become an option for drug-free weight loss, Chinese researchers say. The microbeads are made from green tea and vitamin E, then coated with molecules derived from seaweed. Once ingested, the coating expands, and the green tea molecules and vitamin E bind to and trap partially digested fats in the intestine. Rats on a high fat diet lost 17 per cent of their total body weight when they also consumed the microbeads for a month, while rats fed the high-fat diet but without the microbeads didn't lose weight. The rats fed the microbeads also had less liver damage than rats fed the high-fat diet without microbeads, the researchers found. The microbead group excreted the same amount of fat in their stool as another group of rats on a high-fat diet who received the weight-loss drug orlistat, which also works to remove partly digested fat in the intestines - but without the gastrointestinal side effects seen in the orlistat group. Orlistat is sold over the counter as Alli by GlaxoSmithKline and by prescription as Xenical by Roche. The researchers will present their results at the American Chemical Society Fall 2025 Digital Meeting. In the meantime, they have begun to test the microbeads in humans. The beads are nearly flavorless and could be easily integrated into people's diets, the researchers say. "We want to develop something that works with how people normally eat and live," study leader Yue Wu, a graduate student at Sichuan University, said in a statement. (Reporting by Nancy Lapid; Editing by Mark Porter)

Clinical Result

16 Oct 2024

·www.biospace.com

As Sanofi Preps Consumer Healthcare Sale, Here’s a Look Back at Similar High-Profile Deals

iStock, master1305 Sanofi looks to follow a deep history of Big Pharmas offloading their consumer healthcare businesses. When Sanofi announced last week that it plans to sell a 50% controlling stake of Opella, its consumer helath business, the disclosure echoed similar moves by other Big Pharma companies, including Johnson & Johnson, GSK, Pfizer and Novartis. Just last year, J&J split off Kenvue, creating a standalone company to house iconic brands like Tylenol and Benadryl. Novartis did the same with its generics and biosimilars unit Sandoz as well. But if you look back even further, Roche was the first Big Pharma 20 years ago to portion off its consumer work and hand it off to Bayer. Sanofi is now looking to make a similar move, selling Opella to a private equity firm. The company first set up its consumer healthcare section as a standalone global business unit in 2019, seemingly prepping it for a full spin out at some point, while streamlining down to only priority brands. Those under the Opella banner include seasonal allergy medication Allegra, topical pain relief line IcyHot and constipation drug DulcoLax. As of 2023, the unit had revenue of €5.2 billion ($5.7 billion), with a presence in 150 countries with 11,000 employees. Sanofi telegraphed the split from the consumer healthcare unit a year ago as part of its October 2023 “Play to Win Strategy.” Specifically, the company announced a plan to separate the consumer business entirely and shift its focus to innovative medicines and vaccines. The move would create two separate entities, “each better equipped to pursue its own business strategy,” according to the release, which noted that the separation could happen by the fourth quarter of 2024. And here we are, the final quarter just beginning, and Sanofi is in earnest talks with a potential buyer for Opella. As we wait for that story to unfold, BioSpace takes a look back at how this sort of transaction has gone previously. Kenvue Former parent: Johnson & Johnson New ownership: Standalone company Date of split: August 23, 2023 Brands: Tylenol, Zyrtec, Nicorette, Benadryl, Motrin 2023 revenue: $15.4 billion YOY growth: 5% Kenvue spun out of J&J in August 2023, marking a “historic moment,” according to newly-minted CEO Thibaut Mongon. J&J still has a stake in the company, but Kenvue is otherwise independent . A debt offering and the IPO raised $13.2 billion. When announcing the spin off, J&J CEO Joaquin Duato said the separation “sharpens” the healthcare company’s focus on innovation in pharma and medtech. The separate company is now the largest pure-play consumer health company by revenue, known for brands such as Tylenol, Neosporin, Johnson’s baby soap, Listerine and Neutrogena. Kenvue planned to spend 2024 investing in its brands and boosting prominence on store shelves. Mongon said during a second-quarter earnings call, “Earlier this year, I committed to you that you would see a new Kenvue, the bolder company that is moving quickly to advance our three priorities to reach more consumers effectively, invest further behind our brands, and build a culture of performance and impact.” Sandoz Former parent: Novartis New ownership: Standalone company Date of split: October 4, 2023 Brands: Generics, biosimilars 2023 revenue: $9.6 billion (reported as net sales) YOY growth: 11% Wanting to focus 100% on innovative medicines , Novartis spun off the Sandoz unit, which manufactures generics and biosmiliars, just over a year ago. This transaction was a little different from the others on this list, as Sandoz exclusively manufactures prescription medicines, but it gets lumped in with the rest when talking about major pharmaceutical companies calving off massive portions of their business to focus on innovation. In 2023, Sandoz launched biosimilars for AbbVie’s Humira and J&J’s Stelara. This year, it’s launched a generic for chemotherapy drug paclitaxel and a biosimilar of Regeneron’s Eylea, among many others. CEO Richard Saynor boasted during a second-quarter earnings call in August that Sandoz had grown for the 11th straight quarter. But he also foreshadowed changes that could impact employees, with a multiyear program underway to reduce costs by $200 million annually by 2026. “Coming out of a large pharmaceutical company with a much more complex and layered infrastructure we have plans to reduce layers across the organization and simplify our processes,” Saynor said. Haleon Former parent: GSK/Pfizer New ownership: Standalone company Date of split: July 18, 2022 Brands: Sensodyne, Advil, Voltaren, Theraflu, Centrum 2023 revenue: £11.3 billion ($14.7 billion) YOY growth: 4.1% GSK’s consumer healthcare unit was said to be worth $36 billion at the time of the demerger, which was announced in early 2022. CEO Emma Walmsley said the spin out was coming as the U.K. pharma planned “the most significant corporate change for GSK in the last 20 years.” The unit was formed through a series of M&A deals and divestments, and was partly owned by Pfizer at the time of the sale. GSK held a majority 68% interest while Pfizer had 32%. Brian McNamara, previously the chief of the consumer division at GSK, was put in place as CEO, a role he still holds. Haleon recently upped its stake in a Chinese joint venture called Tianjin TSKF Pharmaceutical, adding another 33% equity interest, and divested ChapStick and other brands, along with a handful of nicotine replacement products. “We love the portfolio we have. We don’t believe we need to do anything with the portfolio to deliver on our guidance that we have given. But that said, we want to proactively and actively manage the portfolio,” McNamara said. He promised that as certain products are offloaded, his team is keeping an eye out for bolt-on M&A opportunities. Both GSK and Pfizer have been lowering their stakes in Haleon in recent months, with Pfizer’s share dropping from 32% to 24% in March, while GSK’s has fallen to just 4.2% ownership. Consumer health business Former parent: Merck KGaA New ownership: Proctor & Gamble Date of split: December 1, 2018 Brands: Neurobion, Nasivin, Bion3 2023 revenue: N/A YOY growth: N/A Germany’s Merck KGaA sold off its consumer health unit to Proctor & Gamble in 2018, perhaps kickstarting the more recent trend we see today. The unit was purchased for €3.4 billion ($3.7 billion), netting €2.7 billion ($2.9 billion) in cash, which Merck put towards reducing debt. The unit’s key brands include Neurobion, Dolo-Neurobion, Femibion, Nasivin and Bion3, primarily sold in Europe, Latin America and Asia. P&G also took on the Merck employees from the unit. P&G has previously had a joint venture with Teva in consumer health, which was terminated with the Merck deal. Roche Consumer Health Former parent: Roche Holdings New ownership: Bayer Date of split: July 2004 Brands: Aleve, Bepanthen, Berocca, Flanax, Redoxon 2023 revenue: N/A YOY growth: N/A Roche and Bayer had been working together in a consumer health joint venture, but the Swiss pharma decided to leave the partnership in 2004. Bayer was happy to pick up the remaining shares plus a few more assets including manufacturing sites. The complex transaction was three deals in one, with the termination of the joint venture, the sale of Roche’s over-the-counter business to Bayer and the out-licensing of an anti-obesity drug called orlistat going to GSK. Consider that, 20 years later, obesity and weight loss has become all the rage in pharma, with Roche investing heavily in the GLP-1 space to keep pace with its peers. Orlistat is still manufactured and sold over-the-counter by none-other than GSK’s former consumer unit Haleon and also as a generic by others.

AcquisitionExecutive ChangeLicense out/in

21 Aug 2024

·www.drugs.com

Semaglutide-Linked Suicidal Ideation ID'd in Disproportionality Analysis

WEDNESDAY, Aug. 21, 2024 -- Semaglutide -associated suicidal ideation has been identified in a disproportionality analysis, according to a study published online Aug. 20 in JAMA Network Open . Georgios Schoretsanitis, M.D., Ph.D., from Northwell Health in Glen Oaks, New York, and colleagues examined potential signals for suicidal and self-injurious adverse drug reactions (ADRs) associated with the glucagon-like peptide 1 receptor agonists semaglutide and liraglutide in a disproportionality analysis. Participants were patients experiencing an ADR, which was suspected as attributable to semaglutide or liraglutide. Overall, 107 and 162 cases of suicidal and/or self-injurious ADRs were reported between November 2000 and August 2023 for semaglutide and liraglutide, respectively. The researchers detected significant disproportionality for semaglutide-associated suicidal ideation (reporting odds ratio, 1.45), which remained significant for those coreporting antidepressant and benzodiazepine use (reporting odds ratios, 4.45 and 4.07, respectively) and compared with dapagliflozin, metformin, and orlistat (reporting odds ratios, 5.56, 3.86, and 4.24, respectively). "We reported a disproportionality signal of suicidal ideation with semaglutide, but not for liraglutide, particularly among patients with coreported antidepressant use, a proxy for affective disorders (a notable exclusion criteria of premarketing clinical trials)," the authors write. One author disclosed ties to the biopharmaceutical industry. Abstract/Full Text Editorial Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultClinical Study

100 Deals associated with Orlistat

External Link

KEGG	Wiki	ATC	Drug Bank
D04028	Orlistat	A08AB01	DB01083

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	European Union	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998
Obesity	Iceland	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998
Obesity	Liechtenstein	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998
Obesity	Norway	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998
Overweight	European Union	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998
Overweight	Iceland	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998
Overweight	Liechtenstein	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998
Overweight	Norway	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metabolic Diseases	Phase 3	Russia	Hoffmann-La Roche, Inc.	01 Apr 2008
Hypertriglyceridemia	Phase 2	United States	The University of Texas Southwestern Medical Center	01 Dec 2015
Hyperlipoproteinemia Type I	Phase 2	United States	The University of Texas Southwestern Medical Center	01 Nov 2015
Diabetes Mellitus	Phase 2	United States	Roche Pharma AG	01 May 1998
Hypertension	Phase 2	United States	Roche Pharma AG	01 May 1998
Sleep Apnea Syndromes	Phase 2	United States	Roche Pharma AG	01 May 1998

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04531176 (EMPOWER-T2D, CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Obesity	74	Weight Management Program (WMP)+Orlistat+liraglutide 3.0 mg+Phentermine / Topiramate Extended Release Oral Capsule+naltrexone/bupropion extended-release (Obesity-centric Approach + AOM)	bmqonlidvd(lmfowaript) = bbdziycath vdgrddzybf (wfgcredsgz, aqtinapsfn - temkzrytug) View more	-	22 Jul 2024
				Weight Management Program (WMP) (Obesity-centric Approach Without AOM)	bmqonlidvd(lmfowaript) = ajwpcxalxk vdgrddzybf (wfgcredsgz, qwjoizhzjv - myrutpjklm) View more
NCT05496075 (ADA2024) Manual	Phase 3	Hyperuricemia \| Obesity	72	Orlistat	unqqbnancl(qnwermqniu): HR = 0.31 (95% CI, 0.11 - 0.85), P-Value = 0.023	Positive	24 Jun 2024
				Placebo
NCT03582722 (CTgov)	Phase 4	Poisoning	100	Multivitamin (Placebo)	kplzbwewwe(jqgfqnygwn) = lnuccytcga yjltmwsjgn (siawrzpnsl, 16.4) View more	-	25 Apr 2024
				Multivitamin+Orlistat (Orlistat Weight Loss Aid)	kplzbwewwe(jqgfqnygwn) = tfsnfdnyob yjltmwsjgn (siawrzpnsl, 17.8) View more
NCT05496075 (Pubmed \| Lipids Health Dis) Manual	Phase 4	Hyperuricemia \| Overweight \| Obesity	72	Orlistat	tggwrmiwxa(zoamprsrle) = There was no significant difference in SUA level between the two groups mkaxkxnsdp (gjaltldoon ) View more	Positive	11 Mar 2024
				Placebo
NCT01351753 (REVIVE, CTgov)	Phase 2	Metabolic Syndrome \| Obesity, Abdominal	128	Metformin (Metformin)	lgefoqxpjj(ujtjnsifrl) = oyipurntbq zgkrblirkg (ewnpjotlps, tjuailiuyz - kefzcpwbuu) View more	-	09 Jun 2021
				Orlistat+Metformin (Metformin + Orlistat)	lgefoqxpjj(ujtjnsifrl) = qlunhkceaz zgkrblirkg (ewnpjotlps, rmhcsafipb - gkrstljwae) View more
ChiCTR-IPR-17011629 (Pubmed \| J Clin Endocrinol Metab)	Not Applicable	Overweight \| Obesity	877	Orlistat	hyprzxsdfp(zowtumpjvm) = ujqictgwwn frualpkgbf (vwnrkbrgot ) View more	Negative	15 May 2021
				Placebo	hyprzxsdfp(zowtumpjvm) = cuyfabhihg frualpkgbf (vwnrkbrgot ) View more
NCT02432209 (FIT-PLESE, CTgov)	Phase 3	Infertility, Female \| Obesity	379	Moderate physical activity+Orlistat (Intensive Lifestyle Mod. Intervention)	drbrzhobdc = tldoyrswkn gsmkystwiv (ksbbfdkbzq, pbikbyxgfl - oogthhfjxg) View more	-	15 Mar 2021
				Moderate physical activity (Standard Lifestyle Intervention)	drbrzhobdc = ojllyxrtye gsmkystwiv (ksbbfdkbzq, dtjqpvjevl - trorklthct) View more
NCT02529631 (Pubmed)	Not Applicable	Overweight \| Obesity	64	Orlistat 60mg	tfkphonsef(jpczpvggos) = ekeuuqvrpy iqpaignlxv (yktbybpozp )	-	01 Jan 2017
				Polyglucosamine	tfkphonsef(jpczpvggos) = nxvasvfknx iqpaignlxv (yktbybpozp )
NCT00704912 (OWL-PCOS, CTgov)	Phase 2	Hyperandrogenism \| Insulin Resistance \| Polyendocrine Metabolic Ovarian Syndrome	217	Orlistat/Meal Replacement/Lifestyle Modification (Lifestyle Intervention)	makuyeqibk = wfufnaohor ywzktzzkkk (modnftripl, ajnczjijwl - niwdnxiyty) View more	-	17 Dec 2015
				Loestrin 1/20 (Oral Contraceptives (OCP))	makuyeqibk = gnurjsbkso ywzktzzkkk (modnftripl, qfytccrlbu - dglhkuurqg) View more
NCT01035333 (CTgov)	Phase 4	Weight Loss \| Obesity	19	Orlistat	itqsftigno(xsloiszcbp) = caomxlspsx ftheckmgto (sxlaofygod, 3.4) View more	-	04 Apr 2014

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis